论文部分内容阅读
替比夫定是一种新型的用于治疗慢性乙型肝炎的左旋核苷类似物,与其他核苷(酸)类似物一样,在长期治疗过程中出现的耐药问题已成为严重影响抗乙型肝炎病毒疗效的突出难题。因此,加强对替比夫定等核苷(酸)类似物耐药机制与耐药对策的研究是非常有意义的。M204I变异是目前唯一确定与替比夫定耐药有关的变异位点。选择合适的初治患者,采用联合治疗,以及加强治疗过程中的监控与管理有可能减少耐药的发生,以取得较好的长期治疗效果。
Telbivudine is a novel levonucleoside analogue for the treatment of chronic hepatitis B and, like other nucleoside (acid) analogues, the problem of drug resistance in the long term treatment has become a serious concern Hepatitis E virus outstanding problems. Therefore, it is of great significance to study the mechanism of drug resistance and resistance to nucleoside (acid) analogues such as telbivudine. The M204I mutation is the only mutation site identified to be resistant to telbivudine. Select the appropriate initial treatment of patients, the use of combination therapy, and strengthen the monitoring and management of the treatment process may reduce the incidence of drug resistance in order to obtain better long-term treatment.